Answers are grounded in this paper and cite their sources.
Background The efficacy of adoptive cell therapy (ACT) in solid tumors is often constrained by an unfavorable tumor microenvironment. Poly(I:C)-mediated innate immune activation can enhance antitumor immunity; however, its impact on the sarcoma immune microenvironment during ACT remains unclear. Methods We evaluated the therapeutic and immune-modulatory effects of poly(I:C) in vaccine-augmented ACT in murine sarcoma models. Flow cytometry was used to assess tumor-infiltrating CD8 + T cells and myeloid populations, and intracellular cytokine staining was performed after ex vivo restimulation. Public bulk RNA-seq datasets from poly(I:C)-treated murine sarcoma and single-cell RNA-seq data from human sarcoma treated with radiotherapy with or without BO-112 were analyzed to identify treatment-associated immune programs. The clinical relevance of TLR3-associated immune activation was evaluated using the TCGA-SARC cohort. Results Poly(I:C) enhanced the efficacy of vaccination-supported ACT, inducing marked tumor control in antigen-positive CMS5a sarcoma and CT26/9m tumor models, with complete regression observed in a subset of tumor-bearing mice. This was associated with increased intratumoral accumulation of adoptively transferred CD8 + T cells, enhanced functional responsiveness of tumor-infiltrating CD8 + T cells, and substantial remodeling of Ly6C/MHCII-defined myeloid cell populations. Bulk transcriptomic analyses of poly(I:C)-treated murine sarcoma identified coordinated interferon-response, antigen-presentation, myeloid/APC, and cytotoxic immune programs, whereas single-cell analysis of human sarcoma identified treatment-associated remodeling of myeloid states and antigen-presentation programs. Higher TLR3 expression and TLR3-associated immune activation signatures were associated with favorable survival in TCGA-SARC. Conclusions Addition of poly(I:C) reshapes the sarcoma immune microenvironment, particularly in myeloid compartments, and enhances the efficacy of ACT against antigen-positive tumors. These findings support further investigation of poly(I:C)-based innate immune activation as a strategy to improve vaccination-supported ACT in solid tumors and suggest that myeloid remodeling associated with enhanced antigen-presentation capacity is linked to improved intratumoral CD8 + T-cell responses.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: